Diethylnorspermine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Diethylnorspermine
Accession Number
DB06445
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
BE-333 / DE-333
Categories
UNII
HLI827Z1ST
CAS number
121749-39-1
Weight
Average: 244.427
Monoisotopic: 244.262697046
Chemical Formula
C13H32N4
InChI Key
UMJJGDUYVQCBMC-UHFFFAOYSA-N
InChI
InChI=1S/C13H32N4/c1-3-14-8-5-10-16-12-7-13-17-11-6-9-15-4-2/h14-17H,3-13H2,1-2H3
IUPAC Name
3,7,11,15-tetraazaheptadecane
SMILES
CCNCCCNCCCNCCCNCC

Pharmacology

Indication

Investigated for use/treatment in renal cell carcinoma, pancreatic cancer, melanoma, and lung cancer.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Diethylnorspermine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
AcemetacinThe therapeutic efficacy of Diethylnorspermine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Diethylnorspermine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Diethylnorspermine.Experimental
AlfuzosinAlfuzosin may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
AliskirenDiethylnorspermine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Diethylnorspermine.Approved, Withdrawn
AmbrisentanDiethylnorspermine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineDiethylnorspermine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Diethylnorspermine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Diethylnorspermine.Approved, Illicit, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Diethylnorspermine.Approved, Investigational, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Diethylnorspermine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Diethylnorspermine.Approved
BarnidipineDiethylnorspermine may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Diethylnorspermine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Diethylnorspermine.Withdrawn
BepridilBepridil may increase the hypotensive activities of Diethylnorspermine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Diethylnorspermine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Diethylnorspermine.Approved, Investigational
BietaserpineBietaserpine may increase the hypotensive activities of Diethylnorspermine.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Diethylnorspermine.Approved
BosentanBosentan may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
BQ-123Diethylnorspermine may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Diethylnorspermine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Diethylnorspermine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Diethylnorspermine.Experimental
BupranololDiethylnorspermine may increase the hypotensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Diethylnorspermine.Approved
CadralazineCadralazine may increase the hypotensive activities of Diethylnorspermine.Experimental
CafedrineDiethylnorspermine may increase the hypotensive activities of Cafedrine.Investigational
CandesartanDiethylnorspermine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Diethylnorspermine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Diethylnorspermine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Diethylnorspermine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Diethylnorspermine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Diethylnorspermine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
ChlorothiazideChlorothiazide may increase the hypotensive activities of Diethylnorspermine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Diethylnorspermine.Approved
CicletanineDiethylnorspermine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Diethylnorspermine.Approved
ClonidineClonidine may increase the hypotensive activities of Diethylnorspermine.Approved
CloranololDiethylnorspermine may increase the hypotensive activities of Cloranolol.Experimental
CryptenamineCryptenamine may increase the hypotensive activities of Diethylnorspermine.Approved
CyclopenthiazideDiethylnorspermine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Diethylnorspermine.Approved, Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Diethylnorspermine.Approved
CymarinCymarin may decrease the cardiotoxic activities of Diethylnorspermine.Experimental
DebrisoquinDebrisoquin may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
DelaprilDiethylnorspermine may increase the hypotensive activities of Delapril.Investigational
DeserpidineDiethylnorspermine may increase the hypotensive activities of Deserpidine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Diethylnorspermine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Diethylnorspermine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Diethylnorspermine.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Diethylnorspermine.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Diethylnorspermine.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
DipyridamoleDipyridamole may increase the antihypertensive activities of Diethylnorspermine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Diethylnorspermine.Approved, Investigational
DorzolamideDorzolamide may increase the hypotensive activities of Diethylnorspermine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Diethylnorspermine.Approved
EfonidipineDiethylnorspermine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Diethylnorspermine.Approved, Vet Approved
EnalaprilatDiethylnorspermine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Diethylnorspermine.Experimental
EpanololDiethylnorspermine may increase the hypotensive activities of Epanolol.Experimental
EpoprostenolEpoprostenol may increase the hypotensive activities of Diethylnorspermine.Approved
EprosartanEprosartan may increase the hypotensive activities of Diethylnorspermine.Approved
FelodipineFelodipine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Diethylnorspermine.Approved
Ferulic acidDiethylnorspermine may increase the hypotensive activities of Ferulic acid.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Diethylnorspermine.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Diethylnorspermine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational, Vet Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Diethylnorspermine.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Diethylnorspermine.Approved
GuanazodineDiethylnorspermine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Diethylnorspermine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
GuanoclorDiethylnorspermine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzDiethylnorspermine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanDiethylnorspermine may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Diethylnorspermine.Experimental
HexamethoniumDiethylnorspermine may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineHydracarbazine may increase the hypotensive activities of Diethylnorspermine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Diethylnorspermine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Diethylnorspermine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
ImidaprilDiethylnorspermine may increase the hypotensive activities of Imidapril.Investigational
IndapamideIndapamide may increase the hypotensive activities of Diethylnorspermine.Approved
IndenololDiethylnorspermine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Diethylnorspermine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Diethylnorspermine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Diethylnorspermine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Diethylnorspermine.Approved
IsradipineIsradipine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Diethylnorspermine.Investigational
LabetalolLabetalol may increase the hypotensive activities of Diethylnorspermine.Approved
LacidipineDiethylnorspermine may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Diethylnorspermine.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
LinsidomineDiethylnorspermine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Diethylnorspermine.Approved
MacitentanDiethylnorspermine may increase the hypotensive activities of Macitentan.Approved
ManidipineDiethylnorspermine may increase the hypotensive activities of Manidipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Diethylnorspermine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
MethoserpidineDiethylnorspermine may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaMethyldopa may increase the hypotensive activities of Diethylnorspermine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Diethylnorspermine.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Diethylnorspermine.Experimental
MetipranololMetipranolol may increase the hypotensive activities of Diethylnorspermine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Diethylnorspermine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
MetyrosineDiethylnorspermine may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Diethylnorspermine.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Diethylnorspermine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Diethylnorspermine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Diethylnorspermine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
MuzolimineDiethylnorspermine may increase the hypotensive activities of Muzolimine.Experimental
NadololNadolol may increase the hypotensive activities of Diethylnorspermine.Approved
NaftopidilDiethylnorspermine may increase the hypotensive activities of Naftopidil.Investigational
NebivololNebivolol may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Diethylnorspermine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
NicorandilDiethylnorspermine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineDiethylnorspermine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineDiethylnorspermine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Diethylnorspermine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
ObinutuzumabDiethylnorspermine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Diethylnorspermine.Withdrawn
OleandrinOleandrin may decrease the cardiotoxic activities of Diethylnorspermine.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Diethylnorspermine.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Diethylnorspermine.Approved
OxprenololOxprenolol may increase the hypotensive activities of Diethylnorspermine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Diethylnorspermine.Approved, Vet Approved
PargylinePargyline may increase the hypotensive activities of Diethylnorspermine.Approved
PenbutololPenbutolol may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Diethylnorspermine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Diethylnorspermine.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Diethylnorspermine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Diethylnorspermine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Diethylnorspermine.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Diethylnorspermine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Diethylnorspermine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Diethylnorspermine.Approved
PinacidilPinacidil may increase the hypotensive activities of Diethylnorspermine.Approved
PindololPindolol may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Diethylnorspermine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Diethylnorspermine.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Diethylnorspermine.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Diethylnorspermine.Approved
PrazosinPrazosin may increase the hypotensive activities of Diethylnorspermine.Approved
ProcaineProcaine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Diethylnorspermine.Experimental
QuinaprilQuinapril may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Diethylnorspermine.Approved
RamiprilRamipril may increase the hypotensive activities of Diethylnorspermine.Approved
RasagilineRasagiline may increase the hypotensive activities of Diethylnorspermine.Approved
RemikirenRemikiren may increase the hypotensive activities of Diethylnorspermine.Approved
RescinnamineDiethylnorspermine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
RiociguatDiethylnorspermine may increase the hypotensive activities of Riociguat.Approved
RituximabDiethylnorspermine may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypotensive activities of Diethylnorspermine.Withdrawn
SaprisartanSaprisartan may increase the hypotensive activities of Diethylnorspermine.Experimental
SelegilineSelegiline may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational, Vet Approved
SelexipagDiethylnorspermine may increase the hypotensive activities of Selexipag.Approved
SildenafilSildenafil may increase the antihypertensive activities of Diethylnorspermine.Approved, Investigational
SitaxentanDiethylnorspermine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilSpirapril may increase the hypotensive activities of Diethylnorspermine.Approved
TadalafilTadalafil may increase the antihypertensive activities of Diethylnorspermine.Approved, Investigational
TalinololDiethylnorspermine may increase the hypotensive activities of Talinolol.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
TemocaprilDiethylnorspermine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerlipressinTerlipressin may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
TetrahydropalmatineDiethylnorspermine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineDiethylnorspermine may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Diethylnorspermine.Approved
TiboloneDiethylnorspermine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Diethylnorspermine.Withdrawn
TimololTimolol may increase the hypotensive activities of Diethylnorspermine.Approved
TolazolineTolazoline may increase the hypotensive activities of Diethylnorspermine.Approved, Vet Approved
TolonidineDiethylnorspermine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Diethylnorspermine.Approved
TorasemideTorasemide may increase the hypotensive activities of Diethylnorspermine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Diethylnorspermine.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Diethylnorspermine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Diethylnorspermine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Diethylnorspermine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Diethylnorspermine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
UdenafilUdenafil may increase the antihypertensive activities of Diethylnorspermine.Approved, Investigational
UnoprostoneDiethylnorspermine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Diethylnorspermine.Investigational
ValsartanValsartan may increase the hypotensive activities of Diethylnorspermine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Diethylnorspermine.Approved
VincamineDiethylnorspermine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineDiethylnorspermine may increase the hypotensive activities of Vinpocetine.Investigational
XipamideDiethylnorspermine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineDiethylnorspermine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Diethylnorspermine.Approved, Investigational, Vet Approved
ZofenoprilDiethylnorspermine may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
4131
ChEMBL
CHEMBL44083

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2TerminatedTreatmentHepatocellular,Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.239 mg/mLALOGPS
logP0.77ALOGPS
logP-0.39ChemAxon
logS-3ALOGPS
pKa (Strongest Basic)10.75ChemAxon
Physiological Charge3ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area48.12 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity76.96 m3·mol-1ChemAxon
Polarizability33.2 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dialkylamines. These are organic compounds containing a dialkylamine group, characterized by two alkyl groups bonded to the amino nitrogen.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Dialkylamines
Alternative Parents
Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Secondary aliphatic amine / Organopnictogen compound / Hydrocarbon derivative / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
a small molecule (CPD-10690)

Drug created on March 19, 2008 10:33 / Updated on July 02, 2018 18:32